Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | GPR3 | P46089 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31286071 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL6938751 | 0.85 | ALDH1A1 (0.52) | ALDH1A1MAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL30623356 | 0.85 | ALDH1A1 (0.52) | ALDH1A1MAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL6756103 | 0.84 | CYP3A4 (0.45) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6756046 | 0.82 | RAB9A (0.45) | ALDH1A1MAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL24445841 | 0.81 | GPR3 (0.48) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL442684 | 0.81 | NR4A1 (0.56) | ALDH1A1MAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL29546263 | 0.81 | NR4A1 (0.56) | ALDH1A1MAPTGAASMN1; SMN2MEN1 | |
| SCHEMBL4615608 | 0.80 | ALDH1A1 (0.60) | ALDH1A1MAPTGAASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL9526864 | 0.79 | NR4A1 (0.54) | ALDH1A1MAPTGAASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479834-B2 | Phenol compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-11-25 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-11981686-B2 | Urea compound having substituent | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-14 | — | — | US | disclosed |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| EP-4067343-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-10-05 | — | — | EP | disclosed |
| US-20220289673-A1 | WDR5-MYC INHIBITORS | VANDERBILT UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
| EP-3915558-A1 | SUBSTITUENT-INCLUDING UREA COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2021-12-01 | — | — | EP | disclosed |
| EP-3421466-B1 | BENZOXAZOLE COMPOUND OR SALT THEREOF, AGRICULTURAL/HORTICULTURAL INSECTICIDE CONTAINING SAID COMPOUND, AND METHOD FOR USING SAME | NIHON NOHYAKU CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| CN-113382767-A | Substituted urea compounds | 第一三共株式会社 | 2021-09-10 | — | — | CN | disclosed |
| CN-1520298-A | Pyrazolopyrimidines as therapeutic agents | �����ʩ���عɷݹ�˾ | 2004-08-11 | — | — | CN | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20030109714-A1 | Transition metal mediated process | ABBOTT GMBH & CO. KG (DE) | 2003-06-12 | — | — | US | disclosed |
| US-20030009034-A1 | Transition metal mediated process | ABBOTT GMBH & CO. KG (DE) | 2003-01-09 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002076960-A1 | TRANSITION METAL MEDIATED PROCESS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981686-B2 | Urea compound having substituent | SIRT6, SIRT1, SIRT2 | ALDH1A1 618/4885MAPT 1249/4885GAA 3552/4885 |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | ALDH1A1 81/4885MAPT 3448/4885GAA 678/4885 |
| US-20220289673-A1 | WDR5-MYC INHIBITORS | MYC, WDR5, MYCBP | ALDH1A1 3953/4885MAPT 1222/4885GAA 3730/4885 |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | SIRT6, SIRT1, SIRT2 | ALDH1A1 618/4885MAPT 1249/4885GAA 3552/4885 |
| US-20030009034-A1 | Transition metal mediated process | TPMT, ABAT, TFAM | ALDH1A1 1136/4885MAPT 675/4885GAA 849/4885 |
| US-20030109714-A1 | Transition metal mediated process | TPMT, ABAT, TFAM | ALDH1A1 1136/4885MAPT 675/4885GAA 849/4885 |
| US-12479834-B2 | Phenol compound or salt thereof | REN, MLX, MYB | ALDH1A1 287/4885MAPT 3207/4885GAA 2659/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | ALDH1A1 3953/4885MAPT 1222/4885GAA 3730/4885 |
| US-20230049402-A1 | NOVEL PHENOL COMPOUND OR SALT THEREOF | MYB, MLX, EP300 | ALDH1A1 235/4885MAPT 3490/4885GAA 3048/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | ALDH1A1 99/4885MAPT 3263/4885GAA 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.